Pharmaceutical

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Mar 21, 2025 - 06:00
Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.
Read the original article

Tags:

Previous Article

FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease

Next Article

Servier and Black Diamond sign deal for solid tumours therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Japanese Kyowa Kirin acquires Orchard to bolster gene therapy pipeline

Japanese Kyowa Kirin acquires Orchard to bolster gene t...

Oct 5, 2023

STAT+: Hospitals struggle to make money on CAR-T cancer therapies, but their fortunes may change

STAT+: Hospitals struggle to make money on CAR-T cancer...

Jul 20, 2023

Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine

Evaxion partners with Afrigen Biologics to develop mRNA...

Sep 21, 2023